Creating nanomedicines from antibodies


Tuesday, 21 July, 2015

A new Australian Research Council (ARC) Linkage grant, valued at $360,000 over three years, will assist ongoing development of antibody technology developed by immuno-oncology company Minomic.

The grant has been awarded to Dr Kristofer Thurecht and Associate Professor Stephen Mahler (The University of Queensland) and Professor Pamela Russell (Queensland University of Technology), with Minomic named as an industry partner.

The researchers’ project aims to develop and optimise technology for the conjugation of nanomaterials with antibodies to create next-generation nanomedicines. A novel antibody developed by Minomic, MIL38, will provide the test bed for the technology.

According to Minomic CEO Dr Brad Walsh, the grant will “support development and commercialisation of new diagnostics and therapeutics for a range of diseases”. The researchers believe the project has the potential to rapidly improve the ligation process between synthetic nanomaterials and biologics, leading to more efficient synthesis of targeted diagnostics.

“The University of Queensland and the Centre for Advanced Imaging are using this high-class scientific platform to perform a range of antibody engineering techniques that are novel and may be applied to existing drugs to improve them dramatically,” said Minomic’s head of research and development, Dr Doug Campbell.

“It is a terrific opportunity for Minomic to be involved from the outset and we welcome this funding to progress this important project.”

Related News

Why a gluten-free diet fails in some coeliac patients

Abnormal immune cells are driving ongoing intestinal inflammation that causes symptoms like...

Giving rotavirus vaccine at birth benefits gut bacteria

Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...

TGA approves donanemab for treatment of early Alzheimer's

The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd